77.4 F
New York
Thursday, July 29, 2021

Pfizer [NYSE: PFE] Announces Acquisition of Amplyx Pharmaceuticals

Must read

Digital Realty [NYSE: DLR] Considering Developing 64 MW Facility in South Korea

Digital Realty Trust, Inc. has shown its intention to build the 64-megawatt facility in Seoul, South Korea. The firm has decided that the...

Why Shares of IZEA Worldwide [NASDAQ: IZEA] Skyrocketing Today?

Shares of IZEA Worldwide, Inc. surged 8.10% at the time of writing on Wednesday. The strong performance of the firm has highlighted the...

BIT Mining [NYSE: BTCM] Ink Purchase Agreement to Buy Bitcoin Mining Machine

BIT Mining Limited has inked a purchase agreement to increase the fleet of bitcoin mining machines. As per the new purchase agreement, the...

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Dyadic International, Inc. disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been...

Pfizer Inc. [NYSE: PFE] has declared the acquisition of Amplyx Pharmaceuticals on Wednesday. Amplyx has gained recognition as a private firm that has pledged to the advancement of therapies for critical illnesses that afflict people with imperiled immune systems.

Presently, the top candidate of the firm is Fosmanogepix (APX001). It is a novel examination asset under progress for the therapy of invasive fungal infections. Each year the world has reported more than 1.5 million cases of invasive fungal infection.

Furthermore, the world has experienced a mortality rate as high as 30-80% across infection types. Fosmanogepix has the ability to target fungal strains repellent to the standard of care therapy. Presently, there are only three classes of antifungal remedies.

The new cure of Amplyx is a ray of hope for both physicians and sufferers. US FDA has not provided any authorization to any novel therapeutic class of antifungal therapies in nearly two decades.

Fosmanogepix Phase II Clinical Trials

Fosmanogepix is presently in Phase II clinical study. The purpose of the study is to assess the safety and potency of both intravenous (IV) and oral formulations for the cure of sufferers with critical invasive fungal infections caused by molds, yeasts, and rare molds.

Furthermore, with this buying of Ampylyx PFE not only acquire Fosmanogepix but also got the ownership of Amplyx’s early-stage pipeline that involves potential antiviral (MAU868) and antifungal (APX2039) cures. The firm has not yet disclosed the terms of the agreement.

More articles

Latest article

Binance, FTX Cut Leverage Limits on Crypto Futures Trading to 20x

Two major cryptocurrency trading platforms Binance Futures and FTX disclosed on Monday that they both have made a remarkable decision related to the crypto...

TD Holdings [NASDAQ: GLG] Inks Letter of Intent with Guangdong Jinbochuang

TD Holdings, Inc. has inked a letter of intent (LOI) with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. and (Jinbochuang) and Hunan Jinmeike...

ASGN [NYSE: ASGN] Acquire IndraSoft Inc

ASGN Incorporated disclosed that it has acquired IndraSoft Inc. IndraSoft Inc has gained recognition as a prominent cybersecurity and digital transformation solutions offeror...

Link Reservations Decides to Accept Bitcoin/Crypto Payments

Link Reservations Inc disclosed Friday that it has decided to start accepting Bitcoin and cryptocurrency payments. This is the major breakthrough for the firm...

Athene [NYSE: ATH] Announces Acquisition of Foundation Home Loans

Athene Holding Ltd. disclosed on Thursday that it has inked a definitive agreement to purchase Foundation Home Loans (FHL). FHL had a £3...

Ping [NYSE: PING] and Anexinet Announces Partnership

Ping Identity Holding Corp. and Anexinet Corporation have both entered into a partnership agreement. The collaboration will integrate Ping Identity’s centralized Identity Access...

Digital Realty [NYSE: DLR] and Brookfield Announces Joint Venture

Digital Realty Trust, Inc.   and Brookfield Infrastructure Partners L.P. and its institutional partners disclosed on Wednesday that they have launched a 50/50 joint...

Red Cat [NASDAQ: RCAT] Announces Acquisition of Teal Drones

Red Cat Holdings, Inc. has inked an agreement on Tuesday to buy Teal Drones in an all-stock transaction. This acquisition will add Teal...